MYBL2 Gene Linked to Uterine Leiomyosarcoma Outcomes
Researchers identified gene expression patterns that may influence survival in patients with this rare cancer.
Updated on Sept. 29, 2026 in Cancer
Scientists have discovered that the MYBL2 gene is frequently amplified in uterine leiomyosarcoma, a rare and aggressive cancer. High levels of MYBL2 mRNA appear to correlate with specific molecular changes and reduced survival times in patients.
Why it matters
Identifying these molecular signatures helps clarify the biology driving this challenging tumor. Understanding these pathways is a critical step toward better risk assessment for those diagnosed with the disease.
Using multi-omics profiling of 87 frozen tissues and an integrated mRNA cohort of 201 samples, researchers found that MYBL2 amplification occurs in 30% of these tumors. Higher mRNA levels showed a hazard ratio of 4.3 for shorter survival, though the clinical role of protein expression remains unclear.
The details
MYBL2-high tumors exhibit an immune-cold microenvironment and significant activation of DNA-replication and mitotic pathways. These tumors also show increased expression of proteins including CDK1, BIRC5, KPNA2, CCNB1, and KIF20A. These findings suggest the gene acts as a driver of uncontrolled cell division, which may explain the link to more aggressive disease progression.
Timeline
September 29, 2026: Publication of the research findings.
Health Landscape
This study applies comprehensive genomic sequencing to rare malignancies, following the methodology established by large-scale projects like the NCI's Cancer Genome Atlas (TCGA). It advances the current standard of care by shifting from histological classification to molecular-level tumor profiling.
Patients and their families should note that these findings are currently confined to research settings and do not yet change routine clinical diagnostics. If you have been diagnosed with uterine leiomyosarcoma, discuss with your oncologist whether molecular tumor testing is relevant to your care.
The takeaway
MYBL2 serves as a potential molecular marker that warrants further investigation to improve prognosis accuracy. Readers should continue to work closely with specialized sarcoma centers to access the latest diagnostic information.
Further reading
For broader context on current diagnostic advancements in oncology, visit our Cancer section.
More information
View the complete findings in the peer-reviewed research article published in NPJ Precision Oncology.
Source note: This article includes information reported by Nature.
